<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:g="http://xbrl.dcca.dk/sob" xmlns:b="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature" xmlns:h="http://xbrl.dcca.dk/mrv" xmlns:f="http://xbrl.dcca.dk/arr" xmlns:d="http://xbrl.dcca.dk/cmn" xmlns:e="http://xbrl.dcca.dk/fsa" xmlns:c="http://xbrl.dcca.dk/gsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByNature http://archprod.service.eogs.dk/taxonomy/20221001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20221001.xsd"><link:schemaRef xlink:type="simple" xlink:href="http://archprod.service.eogs.dk/taxonomy/20221001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20221001.xsd"/><c:InformationOnTypeOfSubmittedReport contextRef="c1">Årsrapport</c:InformationOnTypeOfSubmittedReport><c:IdentificationNumberCvrOfSubmittingEnterprise contextRef="c1">34209936</c:IdentificationNumberCvrOfSubmittingEnterprise><c:NameOfSubmittingEnterprise contextRef="c1">Grant Thornton, Godkendt Revisionspartnerselskab</c:NameOfSubmittingEnterprise><c:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="c1">Stockholmsgade, 45</c:AddressOfSubmittingEnterpriseStreetAndNumber><c:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="c1">2100, København Ø</c:AddressOfSubmittingEnterprisePostcodeAndTown><c:PrecedingReportingPeriodStartDate contextRef="c1">2021-07-01</c:PrecedingReportingPeriodStartDate><c:PredingReportingPeriodEndDate contextRef="c1">2022-06-30</c:PredingReportingPeriodEndDate><c:ReportingPeriodStartDate contextRef="c1">2022-07-01</c:ReportingPeriodStartDate><c:ReportingPeriodEndDate contextRef="c1">2023-06-30</c:ReportingPeriodEndDate><c:IdentificationNumberCvrOfReportingEntity contextRef="c1">41912367</c:IdentificationNumberCvrOfReportingEntity><c:NameOfReportingEntity contextRef="c1">Nature's BioCeuticals Denmark ApS</c:NameOfReportingEntity><c:AddressOfReportingEntityStreetName contextRef="c1">Hedebovej</c:AddressOfReportingEntityStreetName><c:AddressOfReportingEntityStreetBuildingIdentifier contextRef="c1">47</c:AddressOfReportingEntityStreetBuildingIdentifier><c:AddressOfReportingEntityPostCodeIdentifier contextRef="c1">5474</c:AddressOfReportingEntityPostCodeIdentifier><c:AddressOfReportingEntityDistrictName contextRef="c1">Veflinge</c:AddressOfReportingEntityDistrictName><d:NameOfAuditFirm contextRef="c37">Grant Thornton, Godkendt Revisionspartnerselskab</d:NameOfAuditFirm><d:IdentificationNumberCvrOfAuditFirm contextRef="c37">34209936</d:IdentificationNumberCvrOfAuditFirm><d:NameAndSurnameOfAuditor contextRef="c37">Michael Beuchert</d:NameAndSurnameOfAuditor><d:DescriptionOfAuditor contextRef="c37">statsautoriseret revisor</d:DescriptionOfAuditor><d:IdentificationNumberOfAuditor contextRef="c37">mne32794</d:IdentificationNumberOfAuditor><c:AddressOfAuditorStreetName contextRef="c37">Stockholmsgade</c:AddressOfAuditorStreetName><c:AddressOfAuditorStreetBuildingIdentifier contextRef="c37">45</c:AddressOfAuditorStreetBuildingIdentifier><c:AddressOfAuditorPostCodeIdentifier contextRef="c37">2100</c:AddressOfAuditorPostCodeIdentifier><c:AddressOfAuditorDistrictName contextRef="c37">København Ø</c:AddressOfAuditorDistrictName><c:AddressOfAuditorCountry contextRef="c37">Danmark</c:AddressOfAuditorCountry><c:TelephoneNumberOfAuditor contextRef="c37">+45 33 110 220</c:TelephoneNumberOfAuditor><c:EmailOfAuditor contextRef="c1">info@dk.gt.com</c:EmailOfAuditor><c:DateOfGeneralMeeting contextRef="c1">2023-12-12</c:DateOfGeneralMeeting><c:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="c1">Kim Meurs-Gerken</c:NameAndSurnameOfChairmanOfGeneralMeeting><e:ClassOfReportingEntity contextRef="c1">Regnskabsklasse B</e:ClassOfReportingEntity><d:TypeOfAuditorAssistance contextRef="c1">Andre erklæringer uden sikkerhed</d:TypeOfAuditorAssistance><c:ToolForPreparingTheXBRLInstanceDocument contextRef="c1">CaseWare fra Revisorgruppen Danmark</c:ToolForPreparingTheXBRLInstanceDocument><f:AddresseeOfAuditorsReportOnOtherReport contextRef="c1">anpartshaverne</f:AddresseeOfAuditorsReportOnOtherReport><f:SignatureOfAuditorsPlace contextRef="c1">København</f:SignatureOfAuditorsPlace><f:SignatureOfAuditorsDate contextRef="c1">2023-12-12</f:SignatureOfAuditorsDate><g:PlaceOfSignatureOfStatement contextRef="c1">Veflinge</g:PlaceOfSignatureOfStatement><g:DateOfApprovalOfAnnualReport contextRef="c1">2023-12-12</g:DateOfApprovalOfAnnualReport><e:GrossProfitLoss contextRef="c1" unitRef="u5" decimals="0">-848625</e:GrossProfitLoss><e:GrossProfitLoss contextRef="c2" unitRef="u5" decimals="0">-943913</e:GrossProfitLoss><e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="c1" unitRef="u5" decimals="0">477244</e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss><e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="c2" unitRef="u5" decimals="0">477244</e:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss><e:ProfitLossFromOrdinaryOperatingActivities contextRef="c1" unitRef="u5" decimals="0">-1325869</e:ProfitLossFromOrdinaryOperatingActivities><e:ProfitLossFromOrdinaryOperatingActivities contextRef="c2" unitRef="u5" decimals="0">-1421157</e:ProfitLossFromOrdinaryOperatingActivities><e:OtherFinanceExpenses contextRef="c1" unitRef="u5" decimals="0">105821</e:OtherFinanceExpenses><e:OtherFinanceExpenses contextRef="c2" unitRef="u5" decimals="0">95987</e:OtherFinanceExpenses><e:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c1" unitRef="u5" decimals="0">-1431690</e:ProfitLossFromOrdinaryActivitiesBeforeTax><e:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c2" unitRef="u5" decimals="0">-1517144</e:ProfitLossFromOrdinaryActivitiesBeforeTax><e:TaxExpense contextRef="c1" unitRef="u5" decimals="0">3200</e:TaxExpense><e:TaxExpense contextRef="c2" unitRef="u5" decimals="0">0</e:TaxExpense><e:ProfitLoss contextRef="c1" unitRef="u5" decimals="0">-1434890</e:ProfitLoss><e:ProfitLoss contextRef="c2" unitRef="u5" decimals="0">-1517144</e:ProfitLoss><e:TransferredToFromRetainedEarnings contextRef="c1" unitRef="u5" decimals="0">-1434890</e:TransferredToFromRetainedEarnings><e:TransferredToFromRetainedEarnings contextRef="c2" unitRef="u5" decimals="0">-1517144</e:TransferredToFromRetainedEarnings><e:AcquiredIntangibleAssets contextRef="c4" unitRef="u5" decimals="0">170000</e:AcquiredIntangibleAssets><e:AcquiredIntangibleAssets contextRef="c3" unitRef="u5" decimals="0">180000</e:AcquiredIntangibleAssets><e:IntangibleAssets contextRef="c4" unitRef="u5" decimals="0">170000</e:IntangibleAssets><e:IntangibleAssets contextRef="c3" unitRef="u5" decimals="0">180000</e:IntangibleAssets><e:LandAndBuildings contextRef="c4" unitRef="u5" decimals="0">13134400</e:LandAndBuildings><e:LandAndBuildings contextRef="c3" unitRef="u5" decimals="0">13387200</e:LandAndBuildings><e:FixturesFittingsToolsAndEquipment contextRef="c4" unitRef="u5" decimals="0">643332</e:FixturesFittingsToolsAndEquipment><e:FixturesFittingsToolsAndEquipment contextRef="c3" unitRef="u5" decimals="0">857776</e:FixturesFittingsToolsAndEquipment><e:PropertyPlantAndEquipment contextRef="c4" unitRef="u5" decimals="0">13777732</e:PropertyPlantAndEquipment><e:PropertyPlantAndEquipment contextRef="c3" unitRef="u5" decimals="0">14244976</e:PropertyPlantAndEquipment><e:NoncurrentAssets contextRef="c4" unitRef="u5" decimals="0">13947732</e:NoncurrentAssets><e:NoncurrentAssets contextRef="c3" unitRef="u5" decimals="0">14424976</e:NoncurrentAssets><e:CurrentDeferredTaxAssets contextRef="c4" unitRef="u5" decimals="0">0</e:CurrentDeferredTaxAssets><e:CurrentDeferredTaxAssets contextRef="c3" unitRef="u5" decimals="0">3200</e:CurrentDeferredTaxAssets><e:OtherShorttermReceivables contextRef="c4" unitRef="u5" decimals="0">103168</e:OtherShorttermReceivables><e:OtherShorttermReceivables contextRef="c3" unitRef="u5" decimals="0">53907</e:OtherShorttermReceivables><e:ShorttermReceivables contextRef="c4" unitRef="u5" decimals="0">103168</e:ShorttermReceivables><e:ShorttermReceivables contextRef="c3" unitRef="u5" decimals="0">57107</e:ShorttermReceivables><e:CashAndCashEquivalents contextRef="c4" unitRef="u5" decimals="0">100</e:CashAndCashEquivalents><e:CashAndCashEquivalents contextRef="c3" unitRef="u5" decimals="0">100</e:CashAndCashEquivalents><e:CurrentAssets contextRef="c4" unitRef="u5" decimals="0">103268</e:CurrentAssets><e:CurrentAssets contextRef="c3" unitRef="u5" decimals="0">57207</e:CurrentAssets><e:Assets contextRef="c4" unitRef="u5" decimals="0">14051000</e:Assets><e:Assets contextRef="c3" unitRef="u5" decimals="0">14482183</e:Assets><e:RecognisedButNotOwnedAssets contextRef="c1" unitRef="u5" decimals="0">0</e:RecognisedButNotOwnedAssets><e:ContributedCapital contextRef="c4" unitRef="u5" decimals="0">1600000</e:ContributedCapital><e:ContributedCapital contextRef="c3" unitRef="u5" decimals="0">40000</e:ContributedCapital><e:SharePremium contextRef="c4" unitRef="u5" decimals="0">180000</e:SharePremium><e:SharePremium contextRef="c3" unitRef="u5" decimals="0">0</e:SharePremium><e:RetainedEarnings contextRef="c4" unitRef="u5" decimals="0">-2932050</e:RetainedEarnings><e:RetainedEarnings contextRef="c3" unitRef="u5" decimals="0">-1537160</e:RetainedEarnings><e:Equity contextRef="c4" unitRef="u5" decimals="0">-1152050</e:Equity><e:Equity contextRef="c3" unitRef="u5" decimals="0">-1497160</e:Equity><e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsLongterm contextRef="c4" unitRef="u5" decimals="0">15046302</e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsLongterm><e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsLongterm contextRef="c3" unitRef="u5" decimals="0">15930249</e:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsLongterm><e:LongtermLiabilitiesOtherThanProvisions contextRef="c4" unitRef="u5" decimals="0">15046302</e:LongtermLiabilitiesOtherThanProvisions><e:LongtermLiabilitiesOtherThanProvisions contextRef="c3" unitRef="u5" decimals="0">15930249</e:LongtermLiabilitiesOtherThanProvisions><e:ShorttermTradePayables contextRef="c4" unitRef="u5" decimals="0">156748</e:ShorttermTradePayables><e:ShorttermTradePayables contextRef="c3" unitRef="u5" decimals="0">49094</e:ShorttermTradePayables><e:ShorttermLiabilitiesOtherThanProvisions contextRef="c4" unitRef="u5" decimals="0">156748</e:ShorttermLiabilitiesOtherThanProvisions><e:ShorttermLiabilitiesOtherThanProvisions contextRef="c3" unitRef="u5" decimals="0">49094</e:ShorttermLiabilitiesOtherThanProvisions><e:LiabilitiesOtherThanProvisions contextRef="c4" unitRef="u5" decimals="0">15203050</e:LiabilitiesOtherThanProvisions><e:LiabilitiesOtherThanProvisions contextRef="c3" unitRef="u5" decimals="0">15979343</e:LiabilitiesOtherThanProvisions><e:LiabilitiesAndEquity contextRef="c4" unitRef="u5" decimals="0">14051000</e:LiabilitiesAndEquity><e:LiabilitiesAndEquity contextRef="c3" unitRef="u5" decimals="0">14482183</e:LiabilitiesAndEquity><e:OtherInterestExpenses contextRef="c1" unitRef="u5" decimals="0">105821</e:OtherInterestExpenses><e:OtherInterestExpenses contextRef="c2" unitRef="u5" decimals="0">95987</e:OtherInterestExpenses><e:OtherFinanceExpenses contextRef="c1" unitRef="u5" decimals="0">105821</e:OtherFinanceExpenses><e:OtherFinanceExpenses contextRef="c2" unitRef="u5" decimals="0">95987</e:OtherFinanceExpenses><e:IntangibleAssetsGross contextRef="c231" unitRef="u5" decimals="0">180000</e:IntangibleAssetsGross><e:IntangibleAssetsGross contextRef="c233" unitRef="u5" decimals="0">180000</e:IntangibleAssetsGross><e:AmortisationOfIntangibleAssets contextRef="c232" unitRef="u5" decimals="0">10000</e:AmortisationOfIntangibleAssets><e:AccumulatedImpairmentLossesAndAmortisationOfIntangibleAssets contextRef="c233" unitRef="u5" decimals="0">10000</e:AccumulatedImpairmentLossesAndAmortisationOfIntangibleAssets><e:IntangibleAssets contextRef="c233" unitRef="u5" decimals="0">170000</e:IntangibleAssets><e:PropertyPlantAndEquipmentGross contextRef="c84" unitRef="u5" decimals="0">13640000</e:PropertyPlantAndEquipmentGross><e:PropertyPlantAndEquipmentGross contextRef="c89" unitRef="u5" decimals="0">13640000</e:PropertyPlantAndEquipmentGross><e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c84" unitRef="u5" decimals="0">252800</e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><e:DepreciationOfPropertyPlantAndEquipment contextRef="c88" unitRef="u5" decimals="0">252800</e:DepreciationOfPropertyPlantAndEquipment><e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c89" unitRef="u5" decimals="0">505600</e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><e:PropertyPlantAndEquipment contextRef="c89" unitRef="u5" decimals="0">13134400</e:PropertyPlantAndEquipment><e:PropertyPlantAndEquipmentGross contextRef="c99" unitRef="u5" decimals="0">1072220</e:PropertyPlantAndEquipmentGross><e:PropertyPlantAndEquipmentGross contextRef="c101" unitRef="u5" decimals="0">1072220</e:PropertyPlantAndEquipmentGross><e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c99" unitRef="u5" decimals="0">214444</e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><e:DepreciationOfPropertyPlantAndEquipment contextRef="c100" unitRef="u5" decimals="0">214444</e:DepreciationOfPropertyPlantAndEquipment><e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment contextRef="c101" unitRef="u5" decimals="0">428888</e:AccumulatedImpairmentLossesAndDepreciationOfPropertyPlantAndEquipment><e:PropertyPlantAndEquipment contextRef="c101" unitRef="u5" decimals="0">643332</e:PropertyPlantAndEquipment><e:Equity contextRef="c119" unitRef="u5" decimals="0">40000</e:Equity><e:Equity contextRef="c478" unitRef="u5" decimals="0">40000</e:Equity><e:IncreaseOfCapital contextRef="c120" unitRef="u5" decimals="0">1600000</e:IncreaseOfCapital><e:IncreaseOfCapital contextRef="c479" unitRef="u5" decimals="0">0</e:IncreaseOfCapital><e:DecreaseOfCapital contextRef="c120" unitRef="u5" decimals="0">40000</e:DecreaseOfCapital><e:DecreaseOfCapital contextRef="c479" unitRef="u5" decimals="0">0</e:DecreaseOfCapital><e:Equity contextRef="c121" unitRef="u5" decimals="0">1600000</e:Equity><e:Equity contextRef="c480" unitRef="u5" decimals="0">40000</e:Equity><e:IncreaseOfCapital contextRef="c123" unitRef="u5" decimals="0">180000</e:IncreaseOfCapital><e:IncreaseOfCapital contextRef="c485" unitRef="u5" decimals="0">0</e:IncreaseOfCapital><e:Equity contextRef="c124" unitRef="u5" decimals="0">180000</e:Equity><e:Equity contextRef="c486" unitRef="u5" decimals="0">0</e:Equity><e:Equity contextRef="c137" unitRef="u5" decimals="0">-1537160</e:Equity><e:Equity contextRef="c498" unitRef="u5" decimals="0">-20016</e:Equity><e:ProfitLoss contextRef="c138" unitRef="u5" decimals="0">-1434890</e:ProfitLoss><e:ProfitLoss contextRef="c499" unitRef="u5" decimals="0">-1517144</e:ProfitLoss><e:ValueAdjustmentsOfEquity contextRef="c138" unitRef="u5" decimals="0">40000</e:ValueAdjustmentsOfEquity><e:ValueAdjustmentsOfEquity contextRef="c499" unitRef="u5" decimals="0">0</e:ValueAdjustmentsOfEquity><e:Equity contextRef="c139" unitRef="u5" decimals="0">-2932050</e:Equity><e:Equity contextRef="c500" unitRef="u5" decimals="0">-1537160</e:Equity><g:IdentificationOfApprovedAnnualReport contextRef="c1" xml:lang="en">Today, the Managing Director has approved the annual report of Nature's BioCeuticals Denmark ApS for the financial year 1 July 2022 - 30 June 2023.
</g:IdentificationOfApprovedAnnualReport><g:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="c1" xml:lang="en">The annual report has been prepared in accordance with the Danish Financial Statements Act.
</g:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement><g:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="c1" xml:lang="en">I consider the chosen accounting policy to be appropriate, and in my opinion, the financial statements give a true and fair view of the financial position of the Company at 30 June 2023 and of the results of the Company's operations for the financial year 1 July 2022 – 30 June 2023.
</g:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults><g:ConfirmationThatFinancialStatementsAreExemptedFromAuditing contextRef="c1" xml:lang="en">The Managing Director consider the conditions for audit exemption of the 2022/23 financial statements to be met.
</g:ConfirmationThatFinancialStatementsAreExemptedFromAuditing><g:ManagementsStatementAboutManagementsReview contextRef="c1" xml:lang="en">Further, in my opinion, the Management's review gives a true and fair review of the matters discussed in the Management's review.
</g:ManagementsStatementAboutManagementsReview><g:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="c1" xml:lang="en">We recommend that the annual report be approved at the Annual General Meeting.
</g:RecommendationForApprovalOfAnnualReportByGeneralMeeting><d:NameAndSurnameOfMemberOfExecutiveBoard contextRef="c29">Francois Jean-Martin Susini</d:NameAndSurnameOfMemberOfExecutiveBoard><f:DescriptionOfOtherEngagement contextRef="c1" xml:lang="en">We have compiled the financial statements of Nature's BioCeuticals Denmark ApS for the financial year 1 July 2022 - 30 June 2023 based on the company's bookkeeping and on information you have provided.

These financial statements comprise income statement, balance sheet, statement of changes in equity, notes and a summary of significant accounting policies.

We performed this compilation engagement in accordance with International Standard on Related Services 4410 (Revised), Compilation Engagements.

We have applied our expertise in accounting and financial reporting to assist Management in the preparation and presentation of these financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant requirements under the Danish Act on Approved Auditors and Audit Firms and International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) including principles of integrity, objectivity, professional competence and due care.

These financial statements and the accuracy and completeness of the information used to compile them are your responsibility.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile these financial statements. Accordingly, we do not express an audit opinion or a review conclusion on whether these financial statements are prepared in accordance with the Danish Financial Statements Act.
</f:DescriptionOfOtherEngagement><h:DescriptionOfPrimaryActivitiesOfEntity contextRef="c1" xml:lang="en">Description of key activities of the company
The key activities comprise trading and production of medical cannabis and associated activities
</h:DescriptionOfPrimaryActivitiesOfEntity><h:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs contextRef="c1" xml:lang="en">Development in activities and financial matters
The company has in the prior year invested in production facilities and equipment, however have not yet started products of its products. The result is therefore as expected. Since the company is still in a start up phase, the company is dependent on continued financial support of its investors. It is management's expectation that this will be upheld, why the accounts have been prepared on a going concern basis.</h:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs><e:DisclosureOfUncertaintiesRelatingToGoingConcern contextRef="c1" xml:lang="en">1.
Uncertainties relating to going concern
Since the company is still in a start up phase, the company is dependent on continued financial support of its investors. The company has received a letter of support from its investors, why the accounts have been prepared on a going concern basis.


</e:DisclosureOfUncertaintiesRelatingToGoingConcern><e:InformationOnReportingClassOfEntity contextRef="c1" xml:lang="en">The annual report for Nature's BioCeuticals Denmark ApS has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. Furthermore, the company has decided to comply with certain rules applying to reporting class C enterprises.

The accounting policies are unchanged from last year, and the annual report is presented in DKK.
</e:InformationOnReportingClassOfEntity><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue contextRef="c1" xml:lang="en">Gross loss</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="c1" xml:lang="en">Other external expenses include other production, sales, delivery and administrative costs, including costs of energy, marketing, premises, loss on bad debts, lease expenses, etc
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="c1" xml:lang="en">Tax
The tax for the year, whichc consists of the current tax for the year and changes in deferred tax, is recognised in the Income Statement by the share that may be attributed to the profit of the year, and is recognised directly in equity by the share that may be attributed to entries directly to equity.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfIntangibleAssets contextRef="c1" xml:lang="en">
Intangible fixed assets
Patents and licenses are measured at the lower of cost less accumulated amortisaton and the recoverable amount. Patents are amortised over the remaining patent period and licenses are amortised over the period of the agreement, however, no more tan 8 year.  Profit or loss from sale of intangible fixed assets is calculated at the difference between the sale price and the carrying amount at the time of the sale. Profit and loss are recognised in the Income Statement under other operating income or other operating expenses.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfIntangibleAssets><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment contextRef="c1" xml:lang="en">Property, plant, and equipment
Land and buildings is measured at cost plus revaluations and less accrued depreciation and write-down for impairment. Land is not subject to depreciation.

Land and buildings is revaluated on the basis of regular, independent fair-value assessments. Net revaluation at fair value adjustment is recognised directly in equity less deferred tax and tied up in a particular revaluation reserve. Net impairment loss at fair value adjustment is recognised in the income statement.

The depreciable amount is cost plus revaluations at fair value less expected residual value after the end of the useful life of the asset. The amortisation period is fixed at the acquisition date and reassessed annually. If the residual value exceeds the carrying mount of the asset, depreciation is discontinued.

Reversal of previous revaluations and recognised deferred taxes concerning revaluations are recognised directly in company equity.

Other property, plant, and equipment are measured at cost less accrued depreciation and write-down for impairment.

The depreciable amount is cost less any expected residual value after the end of the useful life of the asset. The amortisation period and the residual value are determined at the acquisition date and reassessed annually. If the residual value exceeds the carrying amount, the depreciation is discontinued.

If the amortisation period or the residual value is changed, the effect on amortisation will, in future, be recognised as a change in the accounting estimates.

The cost comprises acquisition cost and costs directly associated with the acquisition until the time when the asset is ready for use.

Depreciation is done on a straight-line basis according to an assessment of the expected useful life:

Buildings Useful life 30 years
Other fixtures and fittings, tools and equipment Useful life 3-5 years
Minor assets with an expected useful life of less than 1 year are recognised as costs in the income statement in the year of acquisition.

Profit or loss derived from the disposal of property, land, and equipment is measured as the difference between the sales price less selling costs and the carrying amount at the date of disposal. Profit or loss is recognised in the income statement as other operating income or other operating expenses.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity contextRef="c1" xml:lang="en">Equity
Share premium
Share premium comprises premium payments made in connection with the issue of shares. Costs incurred for carrying through an issue are deducted from the premium.

The premium reserve can be used for dividend, for issuing bonus shares, and for covering losses.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEquity><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax contextRef="c1" xml:lang="en">Income tax and deferred tax
Current tax liabilities and current tax receivable are recognised in the statement of financial position as calculated tax on the taxable income for the year, adjusted for tax of previous years' taxable income and for tax paid on account.

Deferred tax is measured on the basis of temporary differences in assets and liabilities with a focus on the statement of financial position. Deferred tax is measured at net realisable value.

Deferred tax is measured based on the tax rules and tax rates applying under the legislation prevailing in the respective countries on the reporting date when the deferred tax is expected to be released as current tax. Changes in deferred tax due to changed tax rates are recognised in the income statement, except for items included directly in the equity.

Deferred tax assets, including the tax value of tax losses allowed for carryforward, are recognised at the value at which they are expected to be realisable, either by settlement against tax of future earnings or by set-off in deferred tax liabilities within the same legal tax unit. Any deferred net tax assets are measured at net realisable value.
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax><e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="c1" xml:lang="en">Liabilities
Financial liabilities are recognised at the time of borrowing by the amount of proceed received less transaction costs. In subsequent periods, the financial liabilities are measured at amortised cost equal to the capitalised value when using the effective interest, the difference between the proceeds and the nominal value being recognised in the Income Statement over the loan period.  The amortised cost of the current liabilities corresponds usually to the nominal value. 
</e:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions><!--Aktuelle periode enkelt selskab--><context id="c1"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2022-07-01</startDate><endDate>2023-06-30</endDate></period></context><!--Forrige periode enkelt selskab--><context id="c2"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2021-07-01</startDate><endDate>2022-06-30</endDate></period></context><!--Slutdato forrige periode enkelt selskab--><context id="c3"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2022-06-30</instant></period></context><!--Slutdato aktuelle periode enkelt selskab--><context id="c4"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2023-06-30</instant></period></context><!--CEO1--><context id="c29"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2022-07-01</startDate><endDate>2023-06-30</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfMemberOfExecutiveBoardDimension"><d:memberOfBoardIdentifier>1</d:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--REVISOR1--><context id="c37"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2022-07-01</startDate><endDate>2023-06-30</endDate></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfAuditorDimension"><d:auditorIdentifier>1</d:auditorIdentifier></xbrldi:typedMember></scenario></context><!--Grunde og bygninger aktuel primo--><context id="c84"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2022-07-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:LandAndBuildingsMember</xbrldi:explicitMember></scenario></context><!--Grunde og bygninger aktuel i aaret--><context id="c88"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2022-07-01</startDate><endDate>2023-06-30</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:LandAndBuildingsMember</xbrldi:explicitMember></scenario></context><!--Grunde og bygninger aktuel ultimo--><context id="c89"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2023-06-30</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:LandAndBuildingsMember</xbrldi:explicitMember></scenario></context><!--Andre anlag aktuel primo--><context id="c99"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2022-07-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:FixturesFittingsToolsAndEquipmentMember</xbrldi:explicitMember></scenario></context><!--Andre anlag aktuel i aaret--><context id="c100"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2022-07-01</startDate><endDate>2023-06-30</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:FixturesFittingsToolsAndEquipmentMember</xbrldi:explicitMember></scenario></context><!--Andre anlag aktuel ultimo--><context id="c101"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2023-06-30</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfPropertyPlantAndEquipmentDimension">e:FixturesFittingsToolsAndEquipmentMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel primo--><context id="c119"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2022-07-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel i aaret--><context id="c120"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2022-07-01</startDate><endDate>2023-06-30</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel ultimo--><context id="c121"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2023-06-30</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Overkurs emission aktuel i aaret--><context id="c123"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2022-07-01</startDate><endDate>2023-06-30</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:SharePremiumMember</xbrldi:explicitMember></scenario></context><!--Overkurs emission aktuel ultimo--><context id="c124"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2023-06-30</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:SharePremiumMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel primo--><context id="c137"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2022-07-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel i aaret--><context id="c138"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2022-07-01</startDate><endDate>2023-06-30</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel ultimo--><context id="c139"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2023-06-30</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Erhverv_immat aktuel primo--><context id="c231"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2022-07-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfIntangibleAssetsDimension">e:AcquiredIntangibleAssetsMember</xbrldi:explicitMember></scenario></context><!--Erhverv_immat aktuel i aaret--><context id="c232"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2022-07-01</startDate><endDate>2023-06-30</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfIntangibleAssetsDimension">e:AcquiredIntangibleAssetsMember</xbrldi:explicitMember></scenario></context><!--Erhverv_immat aktuel ultimo--><context id="c233"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2023-06-30</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfIntangibleAssetsDimension">e:AcquiredIntangibleAssetsMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital forrige EKprimo--><context id="c478"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2021-07-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital forrige EKi aaret--><context id="c479"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2021-07-01</startDate><endDate>2022-06-30</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital forrige EKultimo--><context id="c480"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2022-06-30</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Overkurs emission forrige EKi aaret--><context id="c485"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2021-07-01</startDate><endDate>2022-06-30</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:SharePremiumMember</xbrldi:explicitMember></scenario></context><!--Overkurs emission forrige EKultimo--><context id="c486"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2022-06-30</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:SharePremiumMember</xbrldi:explicitMember></scenario></context><!--Overfort res forrige EKprimo--><context id="c498"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2021-07-01</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res forrige EKi aaret--><context id="c499"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><startDate>2021-07-01</startDate><endDate>2022-06-30</endDate></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res forrige EKultimo--><context id="c500"><entity><identifier scheme="http://www.dcca.dk/cvr">41912367</identifier></entity><period><instant>2022-06-30</instant></period><scenario><xbrldi:explicitMember dimension="e:ClassesOfEquityDimension">e:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--DKK enere--><unit id="u5"><measure>iso4217:DKK</measure></unit></xbrl>
